Novo Nordisk AS Class B NOVO B
Trading Information
- Previous Close Price
- DKK 782.90
- Day Range
- DKK 760.40–788.90
- 52-Week Range
- DKK 628.00–1,033.20
- Bid/Ask
- DKK 778.30 / DKK 778.60
- Market Cap
- DKK 3.46 Tril
- Volume/Avg
- 3.4 Mil / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- 38.75
- Price/Sales
- 13.50
- Dividend Yield (Trailing)
- 1.27%
- Dividend Yield (Forward)
- 1.27%
- Total Yield
- 2.03%
Company Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 69,260
- Website
- https://www.novonordisk.com
Competitors
Valuation
|
Metric
|
NOVO B
|
LLY
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 38.75 | 79.49 | 21.46 |
Price/Book Value | 30.80 | 58.90 | 6.08 |
Price/Sales | 13.50 | 20.60 | 4.93 |
Price/Cash Flow | 30.80 | 79.87 | 22.83 |
Price/Earnings
NOVO B
LLY
AZN
Financial Strength
|
Metric
|
NOVO B
|
LLY
|
AZN
|
|---|---|---|---|
Quick Ratio | 0.74 | 0.61 | 0.69 |
Current Ratio | 0.94 | 1.11 | 0.89 |
Interest Coverage | 30.52 | 15.08 | 5.45 |
Quick Ratio
NOVO B
LLY
AZN
Profitability
|
Metric
|
NOVO B
|
LLY
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | 28.75% | 13.15% | 57.63% |
Return on Equity (Normalized) | 89.64% | 69.16% | 151.23% |
Return on Invested Capital (Normalized) | 67.68% | 23.97% | 84.88% |
Return on Assets
NOVO B
LLY
AZN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Byjrgcbch | Ryjp | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zgzkwxbfy | Rqkfg | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Htklhynl | Cbtdw | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lqrsxvgmk | Xdbyntp | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Yjvhvfqn | Vyr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Tlrwnpq | Cnnhg | $29.2 Bil | |||
| Moderna Inc
MRNA
| Wmybslmzc | Mgpf | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tcjgsdsv | Qnrwt | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dkhhcmjx | Hgwtwr | $13.2 Bil | |||
| Incyte Corp
INCY
| Kfskqvwkq | Mrnrs | $13.0 Bil |
United States